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 The neuromodulatory activities of the endocannabinoid 
(EC) system are involved in many human physiological 
and pathological functions ( 1–5 ). It comprises:  i ) two G-
protein-coupled receptors, known as cannabinoid (CB)1 
and CB2;  ii ) endogenous ligands for these two receptors, 
known as ECs, N-arachidonoyl ethanolamine [AEA (anan-
damide)] and 2-arachidonoylglycerol (AG) being the most 
studied; and  iii ) proteins that regulate EC tissue concen-
tration (anabolic and catabolic enzymes), cellular distribu-
tion (EC-binding proteins and transporters), and CB 
receptor activity (CB receptor-interacting proteins) ( 1 ). 
 In addition to AEA and 2-AG, there are a number of 
structurally related compounds, also known as EC-related 
compounds (ERCs), derived from less unsaturated fatty 
acids: N-acylethanolamides (NAEs) such as N-linoleoyl 
ethanolamide (LEA), N-oleoyl ethanolamide (OEA), N-
palmitoyl ethanolamide (PEA), N-palmitoleoyl ethanolamide 
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on membrane phosphatidylinositols, and then being con-
verted to 2-AG by the action of either of two isoforms of the 
same enzyme, the  sn -1-diacylglycerol lipases   and   (DAGL  
and DAGL  ) ( 15, 16 ). 
 In clinical studies, the determination of ECs and ERCs is 
limited by methodological issues which particularly concern 
2-MGs. Both their chemical isomerization and ex vivo gen-
eration are major issues that limit their inclusion as disease/
physiological biomarkers . The aim of the present work is to 
improve current available methodological approaches for a 
better understanding of the biological signifi cance of ECs. 
 MATERIALS AND METHODS 
 Chemicals and laboratory material 
 Ammonium acetate (Am. Ac.), acetic acid, tert-butyl-methyl-
ether (TBME), acetonitrile, and formic acid were from Merck 
(Darmstadt, Germany). 1-AG, 1-AG-d5, 2-AG, 2-AG-d5, 2-AG-d8, 
2-LG, 1-LG, AEA, AEA-d4, AEA-d8, N-docosatetraenoyl ethanol-
amide (DEA), N-dihomo-  -linolenoyl ethanolamide (DGLEA), 
DHEA, DHEA-d4, LEA, LEA-d4, PEA, PEA-d4, POEA, POEA-d4, 
OEA, OEA-d4, and SEA were from Cayman Chemical (Ann 
Harbor, MI). 1-OG and 2-OG were from Sigma-Aldrich (St. Louis, 
MO). 1-OG-d5 and 2-OG-d5 were from Toronto Research 
Chemicals (North York, ON, Canada). FIPI hydrochloride (CAS 
939055-18-2), D609 (CAS 83373-60-8), edelfosine (CAS 77286-
66-9), and GSK 264220A (CAS 685506-42-7) were from Tocris 
Bioscience (Bristol, UK). Orlistat (tetrahydrolipstatin) was from 
Cayman Chemical. KT172, KT109, and RHC 80267 (CAS 83654-
05-1) were from Sigma-Aldrich. KIMAX 16 × 125 mm screw cap 
glass borosilicate tubes were from Kimble Chase (Mexico). Nunc 
1.8 ml cryotube vials were from Thermo Fisher Scientifi c (Rosk-
ilde, Denmark). Ultrapure deionized water was produced by a 
Milli-Q Advantage A10 system from Millipore (Madrid, Spain). 
 Standard solutions 
 The purity of the NAE standards AEA, DEA, DGLEA, DHEA, 
DHEA, LEA, PEA, PEA, POEA, POEA, OEA, and SEA was >98% 
as provided by the manufacturer. Purity of the MG standards was 
>95% for 2-AG, 1-AG, and 2-LG; >94% for 2-OG; >99% for 1-OG; 
and >90% for 1-LG. The 2-MG standards were a combination of 
90% isomer 2 and 10% isomer 1. The isomeric purity of the MG 
standards and their deuterated analogs was verifi ed by injecting 
the individual standard solutions into the LC/MS-MS system with 
the following results: 91.2%, 2-AG; 91.5%, 2-AG-d5; 100%, 1-AG; 
100%, 1-AG-d5; 97.3%, 2-OG; 94.3%, 2-OG-d5; 100%, 1-OG; 
88.0%, 1-OG-d5; 98.7%, 2-LG; and 100%, 1-LG. The isotopic pu-
rity of the deuterated analogs of NAEs and MGs was >99% for all 
compounds. Stock and working standard solutions were pre-
pared in acetonitrile and stored at   20°C. While working stan-
dard solutions of up to 10   g/ml were stable for protracted 
periods of time, a limited solubility was observed at a higher 
concentration (1 mg/ml) of stock solutions of saturated and 
monounsaturated NAEs and MGs after conservation at   20°C . 
Two mixtures of internal standards (ISTDs) were used: ISTD 
mix 1 prepared at 0.01   g/ml AEA-d4, 0.01   g/ml DHEA-d4, 
0.02   g/ml LEA-d4, 0.04   g/ml PEA-d4, 0.04   g/ml OEA-d4, 
0.2   g/ml 2-AG-d5, and 1   g/ml 2-OG-d5; and ISTD mix 2 pre-
pared at 5.0   g/ml 2-AG-d8 and 0.25   g/ml AEA-d8. The two 
mixes of ISTD were spiked into the plasma samples at a fi xed 
volume of 25   l. The structures of the EC analytes and deuterated 
analogs are represented in  Figs. 1  and 2 . 
(POEA), and N-stearoyl ethanolamide (SEA), among others. 
Analogously, for the 2-monoacylglycerol (MG) series, 
there are also homologs such as 2-oleoylglycerol (OG) and 
2-linoleoylglycerol (LG). Most of these molecules do 
not directly bind to CB receptors but may enhance/mod-
ify the actions of ECs (entourage effect) ( 6 ) or display bio-
logical activities related to their interactions with other 
receptors such as GPR119 (OEA, POEA, LEA, 2-OG) ( 7, 8 ), 
transient receptor potential vanilloid type 1 (TRPV1) (OEA), 
GPR55 (PEA), or PPAR-  (OEA) ( 9 ). Finally, two putative 
ECs, N-eicosapentaenoyl ethanolamide (EPEA) and 
N-docosahexaenoyl ethanolamide (DHEA), derived from 
the n-3 polyunsaturated fatty acids, are able to bind with 
low affi nity to the CB1 and CB2 receptors and may have 
biological signifi cance in the brain ( 10, 11 ). 
 A number of publications have been devoted to the 
analysis of ECs in plasma, and an effort has recently been 
made to establish reference intervals for fi ve ECs in hu-
man plasma ( 12 ). As the chemistry and biology of ECs are 
better understood, so is the need to improve measure-
ments in human plasma through greater control of factors 
that introduce variability. At present, such factors still limit 
the interchangeability of EC plasma concentrations from 
clinical studies. It has already been established that the 
chemical properties of ECs, with respect to their stability 
during analytical procedures (extraction solvents, pH con-
ditions, and evaporation of organic solvents) and their 
absorption by glassware and plastic materials, are very rel-
evant factors to take into consideration. A comprehensive 
review has provided a full discussion on these issues ( 13 ) 
and several analytical methods have already taken these 
factors into account ( 12, 14 ). Discrepancies among labora-
tories probably originate from preanalytical sample pro-
curement protocols and compound-specifi c factors. 
 Concerning biological matrices, ECs are unstable in those 
where enzymes are involved in their synthesis and clearance: 
the fatty acid amide hydrolase hydrolyzes AEA to arachidonic 
acid and ethanolamine, and the MG lipase is responsible for 
the hydrolysis of 2-AG to arachidonic acid and glycerol. Nev-
ertheless, accumulated experience suggests that the incor-
poration of unspecifi c enzyme inhibitors of amidases, esterases, 
and proteases, such as PMSF, to sample collection tubes is 
not justifi ed. However, blood-containing tubes not centri-
fuged immediately in cold conditions after withdrawal may 
cause artifactual exaggerated NAE concentrations due to ex 
vivo release of from erythrocytes or leukocytes ( 12 ). Addi-
tionally, it has been reported that ex vivo synthesis of 2-AG for 
plasma preserved at room temperature and abundant 
2-AG/1-AG isomerization is due to sample analysis condi-
tions ( 12, 14 ). The two main ECs, AEA and 2-AG, are pro-
duced from different biosynthetic pathways. AEA is generated 
from N-arachidonoyl phosphatidylethanolamines by several 
possible biosynthetic routes with multiple enzymes im-
plicated: the N-acyl phosphatidylethanolamine-specific 
phospholipase D, the   ,  -hydrolase-4 (ABHD4), the glyc-
erophosphodiesterase-1 (GDE1), a soluble phospholipase 
A2, an unidentifi ed phospholipase C, and phosphatases ( 15 ). 
In contrast, the biosynthetic precursors for 2-AG, the  sn -1-
acyl-2-AGs, are mostly produced by phospholipase C  acting 
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 Sample preparation 
 Freshly extracted blood from human volunteers was collected in 
10 ml K2E 18.0 mg (EDTA) BD Vacutainer tubes and centrifuged 
immediately for 15 min at 2,800  g in a refrigerated centrifuge (4°C). 
Plasma was then immediately separated from the blood and distrib-
uted in aliquots for further processing or stored at   80°C. Discarded 
human plasma batches from the Blood Bank of Hospital del Mar of 
Barcelona were used for the validation experiments. 
 Plasma samples were thawed in less than 30 min at room tem-
perature and processed on ice. Aliquots of 0.5 ml were trans-
ferred into glass borosilicate tubes, spiked with 25   l of ISTD mix 
 Human volunteers 
 Three human male volunteers were recruited for the pro-
curement of blood samples following protocol MUESBIOL/1 
(protocol for the collection of biological samples for biomedi-
cal research studies). Twenty-fi ve female healthy control volun-
teers with a BMI of <25 kg/m 2 were recruited for the procurement 
of blood samples following the TANOBE protocol. Both proto-
cols were approved by the Ethical Committee of Parc de Salut 
Mar Barcelona (CEIC-PSMAR) and comply with the Declara-
tion of Helsinki. An informed consent was obtained from the 
human subjects. 
 Fig.  1. Structures of the ECs and ERCs. 
 Fig.  2. Structures of the deuterated analogs of ECs and ERCs. 
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(MRM) mode was employed for quantifi cation. The experimental 
MS conditions for each compound are listed in  Tables 1  and 2 . 
 Linearity 
 The linearity of the method was assessed for seven surrogated 
analytes (SAs) by construction of calibration curves using plasma 
samples spiked with deuterated analogs of NAEs and MGs. Analy-
sis was performed in quadruplicate for the following SAs: AEA-d4, 
LEA-d4, PEA-d4, OEA-d4, DHEA-d4, 2-AG-d5, and 2-OG-d5. The 
ISTDs were 2-AG-d8 and AEA-d8 (ISTD mix 2), which have ad-
ditional deuterium atoms in their structure. 2-AG-d8 was used as 
ISTD of 2-MGs, and AEA-d8 as ISTD of NAEs. The regression 
analyses of the calibration curves were calculated with SPSS 12.0 
with a 1/x weighting factor. 
 Quantifi cation 
 Experimental LC/MS-MS parameters for the detection of ana-
lytes and the deuterated analogs are presented in  Tables 1 and 2 . 
The quantifi cation of the SAs was calculated by interpolation of 
the response ratios on the calibration curves. The quantifi cation 
of the authentic analytes was carried out by isotope dilution 
with the following formula: [EC]ng/ml = (ng ISTD × analyte re-
sponse)/(ISTD response × RF × ml aliquot volume). The re-
sponse factor (RF) was calculated as the ratio of the response 
area of the analyte divided by the response area of its ISTD for a 
standard solution mix directly injected without extraction into 
the LC/MS-MS system and in which equal amounts of the analyte 
1 or mix 2, diluted up to 1 ml with 0.1 M Am. Ac. buffer (pH 4.0), 
extracted with 6 ml of TBME, and centrifuged (3,500 rpm, 5 min) 
at room temperature. The organic phase was transferred to clean 
tubes, evaporated (40°C, 20 min) under a stream of nitrogen, 
and extracts were reconstituted in 100   l of a mixture of 
water:acetonitrile (10:90, v/v) with 0.1% formic acid (v/v) and 
transferred to HPLC vials. Twenty microliters were injected into 
the LC/MS-MS system. 
 LC/MS-MS analysis 
 An Agilent 6410 triple quadrupole mass spectrometer (Agilent 
Technologies, Wilmington, DE) equipped with a 1200 series bi-
nary pump, a column oven, and a cooled autosampler (4°C) was 
used. Chromatographic separation was carried out with a Waters 
C18-CSH column (3.1 × 100 mm, 1.8   m particle size) maintained 
at 40°C with a mobile phase fl ow rate of 0.4 ml/min. The composi-
tion of mobile phase A was 0.1% (v/v) formic acid in water and 
mobile phase B was 0.1% (v/v) formic acid in acetonitrile. The 
initial conditions were 40% B. The gradient was fi rst increased lin-
early to 90% B over 4 min, then increased linearly to 100% B over 
5 min and maintained at 100% B for 3 min, to return to initial 
conditions for a further 4 min with a total run time of 16 min. The 
ion source was operated in the positive electrospray mode. A des-
olvation gas temperature of 350°C and a gas fl ow rate of 10 l/min 
were used. The pressure of the nebulizer was set at 40 psi and the 
capillary voltage at 4,000 V. The multiple reaction monitoring 
 TABLE 1. Experimental LC/MS-MS parameters for the analyte detection 
Analyte MW T (min) CV (%) P ( m/z ) Q ( m/z ) I ( m/z ) F (V) CE (eV) ISTD RF a 
2-AG 378.6 7.65 0.08 379.2 287 269, 203 135 12 2-AG-d5 1.00
1-AG 378.6 7.77 0.30 379.2 287 269, 203 135 12 2-AG-d5 1.00
2-LG 354.5 7.76 0.06 355.2 263 245, 337 135 12 2-OG-d5 0.79
1-LG 354.5 7.94 0.08 355.2 263 245, 337 135 12 2-OG-d5 0.79
2-OG 356.5 8.61 0.41 357.3 265 247, 339 135 12 2-OG-d5 1.00
1-OG 356.5 8.82 0.08 357.3 265 247, 339 135 12 2-OG-d5 1.00
AEA 347.5 7.22 0.07 348.3 62 44, 287 135 12 AEA-d4 1.00
DEA 375.6 7.99 0.08 376.3 62 44 135 12 AEA-d4 1.26
DGLEA 349.6 7.61 0.08 350.2 62 44 135 12 AEA-d4 1.68
DHEA 371.6 7.11 0.07 372.6 62 44 135 12 DHEA-d4 1.00
EPEA 345.5 6.66 0.13 346.2 62 44 135 12 AEA-d4 1.00
LEA 323.5 7.26 0.07 324.5 62 44 135 12 LEA-d4 1.00
  -LEA 321.5 6.66 0.11 322.2 62 44 135 12 LEA-d4 1.00
OEA 325.5 8.05 0.06 326.1 62 44, 309 135 12 OEA-d4 1.00
PEA 299.5 7.81 0.07 300.1 62 44, 283 135 12 PEA-d4 1.00
POEA 297.5 6.94 0.08 298.2 62 44 135 12 PEA-d4 1.00
SEA 327.5 9.11 0.07 328.1 62 44, 311 135 12 OEA-d4 1.00
MW, molecular weight; T, retention time; P, precursor ion; Q, quantifi er product ion; I, identifi er(s) product 
ion(s); F, fragmenter; CE, collision energy.
 a Response factor of the analyte versus the internal standard.
 TABLE 2. Experimental LC/MS-MS parameters for the deuterated analogs detection 
Deuterated Analog MW T (min) Q1 ( m/z ) Q3 ( m/z ) F (V) CE (eV)
2-AG-d5 383.6 7.63 384.3 287 135 12
1-AG-d5 383.6 7.77 384.3 287 135 12
2-AG-d8 386.6 7.59 387.5 295 135 12
2-OG-d5 361.6 8.59 362.2 265 135 12
1-OG-d5 361.6 8.79 362.2 265 135 12
AEA-d4 351.6 7.21 352.2 66 135 12
AEA-d8 355.6 7.19 356.2 62 135 12
DHEA-d4 375.6 7.09 376.3 66 135 12
LEA-d4 327.5 7.24 328.5 66 135 12
OEA-d4 329.6 8.04 330.4 66 135 12
PEA-d4 303.5 7.79 304.4 66 135 12
MW, molecular weight; T, retention time; Q1, precursor ion; Q3, product ion; F, fragmenter; CE, collision 
energy.
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 Accuracy was calculated as the percentage of difference be-
tween the observed concentration and the nominal concentra-
tion. The nominal concentration was calculated as the expected 
concentration on day 1 of the QC sample after the spiking pro-
cess, taking into account the basal EC and ERC concentrations. A 
percentage of difference less than 15% for QC-M and QC-H, and 
less than 20% for QC-L was considered acceptable. 
 Imprecision was calculated as the standard error deviation of 
the QC sample replicates. A standard error deviation less than 
15% for QC-M and QC-H, and less than 20% for QC-L was con-
sidered acceptable. 
 Recovery and matrix effect 
 Recovery and matrix effect were evaluated in plasma from six 
different sources with deuterated analogs as SAs analyzed in trip-
licate. First, each batch of plasma was divided into two pools; one 
pool was spiked with ISTD mix 1 and mix 2 and extracted, while 
the other pool was spiked with ISTD mix 1 and mix 2 after extrac-
tion. Second, ISTD mix 1 and mix 2 were also spiked into clean 
glass tubes, evaporated, and reconstituted. Finally, extracted sam-
ples and pure standards were analyzed by LC/MS-MS. Recovery 
was calculated as the response of the SAs of samples spiked be-
fore extraction versus samples spiked after extraction. The ma-
trix effect was calculated as the response of the SAs of samples 
spiked after extraction versus the pure standards. Additionally, 
the CV of the ratio of the SAs with the ISTD of the six plasma 
sources was calculated. 
 Stability of the analytes on reinjection 
 The stability of the reconstituted extract solutions on HPLC 
vials was tested with the reinjection of a batch in which the vials 
were kept at 4°C for 24 h and another batch with the vials kept at 
  20°C for 10 days. 
 Stability of the isomers 1 and 2 of MGs in the 
biological matrix 
 The stability of the isomers 1 and 2 of MGs to isomerization 
(or acyl migration) in the biological matrix was assessed by 
measuring the ratio between the isomers after preservation of 
the plasma at different times and temperatures. For that, one 
batch of human plasma from the blood bank was spiked with 
2-OG-d5 and 2-AG-d5 and another batch was spiked with 
1-OG-d5 and 1-AG-d5. Samples were analyzed by LC/MS-MS 
and the ratios of the 1 and 2 isomers of both batches were 
calculated. The spiked standards, dissolved in mobile phase, 
were also injected directly into the LC/MS-MS system and the 
and ISTD were present. A deuterated form was not commercially 
available for some analytes, so a deuterated analog of another 
NAE or MG with a similar structure was used as ISTD. ISTD mix 
1 was used for the quantifi cation of authentic analytes. This fi t-
for-purpose approach could be employed due to the fact that the 
basic structure of the NAEs and the MGs is the same, the only 
difference being the length of the hydrocarbon chain and the 
number and position of double bonds. For some analytes the RF 
was considered 1.0 because the differences in the absolute re-
sponse were less than 10% ( Table 1 ). We found that the responses 
of 2-AG-d8 and AEA-d8 were considerably lower than their non-
deuterated forms (approximately 10-fold), although, as they were 
not used in the isotope dilution quantifi cation method, calcula-
tions were not affected. The decreased response was probably 
due to the different position of the deuterium atoms in the struc-
ture of the d8 analog (and next to the double bonds) compared 
with the d4 and d5 analogs ( Fig. 2 ). In our LC/MS-MS condi-
tions, responses of the 1-MG and 2-MG isomers were the same. 
 Limits of detection and quantifi cation 
 The mathematical estimates of the limits of detection (LODs) 
and lower limits of quantifi cation (LLOQs) of the SAs were 
inferred from the equations of the curves by the following for-
mulas: LOD ng/ml = (SD of the replicates of the lowest concen-
tration on calibrator/slope) × 3 and LLOQ ng/ml = (SD of the 
replicates of the lowest concentration on calibrator/slope) × 10. 
Additionally, the LLOQs of the SAs were verifi ed experimen-
tally by a six replicate analyses of plasma spiked with d4 or d5 
deuterated forms of NAEs and 2-MGs at the following concentra-
tions: PEA-d4, 0.1 ng/ml; OEA-d4, 0.1 ng/ml; LEA-d4, 0.1 ng/ml; 
AEA-d4, 0.02 ng/ml; DHEA-d4, 0.02 ng/ml; 2-AG-d5, 0.75 ng/ml; 
and 2-OG-d5, 2.5 ng/ml. The samples were further spiked with 
ISTD mix 2, which contained 2-AG-d8 and AEA-d8, and were ana-
lyzed by LC/MS-MS. The ratio of the SAs and their ISTDs was 
calculated. A coeffi cient of variation (CV) of the ratios of less 
than 20% and a signal to noise ratio greater than three were con-
sidered acceptable. 
 A dilution integrity experiment was carried out for lower sam-
ple volumes down to 50   l, with no signifi cant differences in con-
centration. However, the standard volume of the method was set 
at 0.5 ml in order to be able to quantify the ECs and ERCs with 
lower endogenous concentrations. 
 Accuracy and imprecision 
 The within-day and between-day accuracy and imprecision 
of the method were evaluated by the quadruplicate analysis of 
quality control (QC) samples at three concentration levels [QC-
low (L), QC-mid (M), and QC-high (H)] over a 3 day validation 
protocol. The QC samples were prepared by spiking a batch of 
plasma on top of its basal EC and ERC concentrations. QC-L was 
spiked at 0.05 ng/ml POEA, DGLEA, EPEA, ALA, LEA, AEA, 
DEA, and DHEA; 1 ng/ml 2-AG, PEA, OEA, and SEA; and 5 ng/
ml 2-OG and 2-LG. QC-M was spiked at 0.5 ng/ml POEA, 
DGLEA, EPEA, LEA, N-  -linolenoyl ethanolamide (  -LEA), 
AEA, DEA, and DHEA; 5 ng/ml 2-AG, PEA, OEA, and SEA; and 
50 ng/ml of 2-OG and 2-LG. QC-H was spiked at 2.5 ng/ml 
POEA, DGLEA, EPEA, LEA,   -LEA, AEA, DEA, and DHEA; 
25 ng/ml 2-AG, PEA, OEA, and SEA; and 250 ng/ml 2-OG and 
2-LG. Aliquots of each QC were distributed into cryotubes and 
stored at   80°C until analysis. The samples were randomly ana-
lyzed in order to assess carry over. 
 Aliquots of 0.5 ml of the QC samples were spiked with ISTD 
mix 1 at the following amounts of deuterated analogs: 0.25 ng 
AEA-d4, 0.25 ng DHEA-d4, 0.50 ng LEA-d4, 1 ng PEA-d4, 1 ng 
OEA-d4, 5 ng 2-AG-d5, and 25 ng 2-OG-d5; and analyzed by LC/
MS-MS. The quantifi cation was done by isotope dilution. 









 TBME:water (6:1, v/v) a 0.59 0.32
 TBME:water (6:1, v/v) b 0.53 0.20
 TBME:Am. Ac. 0.1 M, pH 4.0 (6:1, v/v) a 0.10 0.09
 Toluene:water (6:1, v/v) a 1.40 0.47
Standard solution 0.06 0.05
The stability of the isomerization of isomer 2 to isomer 1 during 
extraction and evaporation steps was assessed by analyzing the ratio 
(ISO1/ISO2) of plasma spiked with standard solutions of 2-AG-d5 and 
2-OG-d5 subjected to liquid-liquid extraction compared with standard 
solutions dissolved in mobile phase injected directly into the LC/MS-
MS system. ISO1, isomer 1; ISO2, isomer 2 .
 a Reused clean tubes.
 b New silanized tubes.
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KT109, and GSK 264220A. Stock inhibitor solutions were pre-
pared in ethanol, except D609 that was prepared in water. The 
volume of spiking solution added was less than 2% with respect 
to the plasma aliquot volume. Plasma was distributed into cryo-
tubes for the incubation experiments. Edelfosine is a phosphati-
dylinositol phospholipase C inhibitor (IC 50 = 9.6   M). D609 is 
a phosphatidylcholine-specifi c phospholipase C inhibitor ( K i = 
6.4   M). FIPI is a phospholipase D 2 and D 1 inhibitor (IC 50 = 20 
and 25 nM, respectively ). Orlistat is a gastric and pancreatic lipase 
inhibitor and a nonselective DAGL  and DAGL  inhibitor (IC 50 = 
60 and 100 nM, respectively). RHC 80267 is a nonselective DAGL 
inhibitor (IC 50 = 4   M). KT172 and KT109 are selective DAGL  
inhibitors (IC 50 = 60 and 42 nM, respectively) and also DAGL  
inhibitors (IC 50 = 0.14 and 2.3   M, respectively). GSK 264220A is 
an endothelial lipase and a lipoprotein lipase inhibitor (IC 50 = 
0.13 and 0.10   M, respectively). The effect of the blood collec-
tion tube on the MG production was assessed on EDTA (K2E, 18 mg) 
or Lithium heparin (LH, 170 IU) in 10 ml BD Vacutainer 
tubes with or without the presence of the inhibitor . All the in-
hibitors were tested with EDTA-plasma while Orlistat and GSK 
264220A were additionally tested on heparin-plasma. The esti-
mation of the IC 50 of Orlistat for the generation of 2-AG, 2-LG, 
and 2-OG was done in EDTA-plasma samples from three human 
volunteers with the following added concentrations of Orlistat: 0, 
50, 150, 450, 900, 1,500, and 2,500 nM. Control plasma samples 
were kept at 4°C for 2 h until analysis. The percentage of inhibi-
tion was calculated with respect to the levels at concentration of 
inhibitor 0 of each plasma source. The data were modeled by the 
software GraphPad Prism 5 with the inhibition model: log [in-
hibitor] versus percent inhibition and the IC 50 s for 2-AG, 2-LG, 
and OG were calculated. 
 Stabilization of MG measures in plasma with Orlistat 
 Blood extracted from 25 human female volunteers was col-
lected in 10 ml K2E 18.0 mg (EDTA) BD Vacutainer tubes and 
centrifuged immediately at 2,800  g in a refrigerated centrifuge 
(4°C). Plasma of each volunteer was separated immediately from 
the blood and two equal 0.6 ml aliquots were obtained. One aliquot 
was spiked at 3.35   M with 5   l of Orlistat solution (200   g/ml, 
ethanol). Both aliquots were stored at   80°C until EC analysis 
with our standard procedure. 
 RESULTS AND DISCUSSION 
 Method development 
 While some solid phase extraction methods were tried, 
recovery was diffi cult to optimize due to the varying struc-
tures of the analyzed compounds (NAEs and MGs). The 
isomer ratio was calculated. Additionally, in another experiment, 
the isomerization of endogenous MGs (2/1-AG, 2/1-LG, and 
2/1-OG) was assessed in freshly obtained plasma samples from 
human volunteers preserved 2 h at 4ºC or room temperature . 
 Inhibition experiments of the ex vivo generation 
of MGs from plasma 
 Blood was obtained from human volunteers and processed im-
mediately. The rate of production of MGs from the separated 
plasma was assessed by EC analysis after incubation for 2 h at RT 
under agitation. Basal EC levels (time 0) were estimated by im-
mediate EC analysis. A set of potential inhibitors of MG produc-
tion were tested by spiking the plasma before incubation for 2 h 
at RT at different concentrations of inhibitors. In several experi-
ments, the following phospholipase and lipase inhibitors were 
tested: edelfosine, D609, FIPI, Orlistat, RHC 80267, KT172, 
 Fig.  3. LC/MS-MS chromatogram of EC and ERC profi le of a hu-
man plasma sample. 
 TABLE 4. Recovery and matrix interference of the SAs in plasma 
Surrogate Analyte ISTD Recovery (%) Matrix Effect (%) CV (%)
PEA-d4 OEA-d4 96 ± 11   26 ± 4.7 3.0
LEA-d4 OEA-d4 96 ± 7.1   19 ± 4.8 3.0
OEA-d4 PEA-d4 95 ± 8.4   19 ± 5.8 3.4
AEA-d4 AEA-d8 95 ± 7.9   15 ± 4.9 3.5
DHEA-d4 AEA-d4 89 ± 7.6   11 ± 6.0 2.9
AEA-d8 AEA-d4 84 ± 8.7   8.0 ± 5.0 4.2
2-OG-d5 2-AG-d5 84 ± 8.0   40 ± 5.8 7.9
2-AG-d5 2-AG-d8 85 ± 7.8   27 ± 4.0 3.9
2-AG-d8 2-AG-d5 81 ± 6.8   16 ± 4.3 4.9
Mean ± SD of the recovery and matrix effect of the surrogate analytes in plasma of six different sources and 
analyzed in triplicate; CV of the ratio of the SAs with the ISTDs of the six plasma sources.
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authors ( 12, 14 ). However, this is most likely due to the 
longer evaporation time of toluene compared with TBME, 
which in our experiment was relevant due to the amount 
of solvent used (6 ml) in the liquid-liquid extraction. The 
standard solutions were prepared in acetonitrile because 
methanol and other protic solvents promote the isomer-
ization of isomer 2 into isomer 1 of MG ( 13 ). No differ-
ences were observed between extraction tubes that were 
clean, reused ones, or new silanized tubes. 
 We found optimal recoveries and peak shapes with 
the reconstitution of the extract in a mixture of water:
acetonitrile (10:90) with 0.1% formic acid. The EC and 
ERC profi les were separated by reverse phase gradient 
chromatography in a C18 column ( Fig. 3 ), because with a 
C8 column complete separation of the MG isomers was 
not possible. Acetonitrile was used as the organic mobile 
phase, as we observed that methanol also promoted 
2-MG/1-MG isomerization if present in the mobile phase. 
Formic acid at 0.1% v/v was employed as an additive of the 
mobile phase to promote the positive ionization of NAEs 
and MGs. The parent ion adducts selected for fragmenta-
tion in the mass spectrometer were in the form of [M+H] + . 
The product ion  m/z 62, which corresponds to etha-
nolamine, is characteristically generated by fragmentation 
of NAEs; while a neutral loss of 92 Da , which corresponds 
liquid-liquid extraction methods provided the best overall 
recoveries for ECs and ERCs. In order to assess a method 
to stabilize the original isomeric ratio after the extraction 
and evaporation steps, 0.5 ml plasma samples were spiked 
with the deuterated analog isomers 2-AG-d5 and 2-OG-d5, 
extracted, and analyzed by LC/MS-MS to evaluate the gen-
eration of 1-AG-d5 and 1-OG-d5 by chemical isomerization 
or acyl migration ( Table 3 ). Several liquid-liquid extrac-
tion methods were tested: TBME or toluene as extraction 
solvents, Am. Ac. buffer 0.1 M at pH 4.0, or water as aque-
ous solvents, and new silanized borosilicate glass tubes (or 
clean reused tubes) to test for the activity of catalytic si-
lanols. Aqueous solvents were used to reduce viscosity and 
control plasma pH. Elevated temperatures, presence of se-
rum albumin in the sample, and high pH values have been 
reported to accelerate 2-AG/1-AG acyl migration ( 13, 14, 
17 ). It is worth noting that commercially available solu-
tions of 2-AG and other 2-MG usually contain 5–10% 1-MG. 
Therefore, it seems impossible to completely avoid 
2-MG/1-MG isomerization. The solvent that best preserved 
the original deuterated MG isomeric ratio of the sample 
after extraction was the mixture 6:1 TBME: 0.1 M Am. Ac. 
buffer (pH 4.0). In our experimental conditions, we ob-
served that TBME preserved the 2-MG/1-MG ratio better 
than toluene, which was the solvent of choice for other 
 TABLE 5. Imprecision and accuracy 
Analyte
Within Run Between Run
Imprecision (%) Accuracy (%) Imprecision (%) Accuracy (%)
QC-L QC-M QC-H QC-L QC-M QC-H QC-L QC-M QC-H QC-L QC-M QC-H
2-AG 8.7 9.0 7.2 88.7 91.0 75.6 11.0 18.4 14.8 88.4 71.7 83.3
2/1-AG 6.7 5.7 5.7 96.9 96.4 93.5 7.4 14.3 8.2 88.7 93.2 102.8
2-LG 11.0 12.8 5.9 95.8 91.3 77.2 16.2 18.2 19.5 80.2 76.3 83.2
2/1- LG 5.4 8.5 5.7 94.9 100.6 104.7 11.2 4.8 9.6 91.4 101.2 109.6
2-OG 10.6 7.6 8.6 86.9 92.9 83.2 10.6 18.3 8.2 88.4 77.5 89.5
2/1-OG 9.7 8.7 6.9 95.3 89.9 97.0 12.1 11.2 5.6 90.8 85.1 104.4
AEA 4.6 6.1 4.3 92.9 88.7 89.6 9.8 10.2 4.8 92.1 92.9 89.4
DEA 4.5 6.1 5.2 91.6 91.4 93.0 11.9 6.9 5.3 95.0 94.1 95.2
DGLEA 7.7 6.1 4.1 97.0 97.6 95.0 10.4 9.0 5.4 101.2 97.5 98.3
DHEA 4.7 8.8 3.0 94.6 92.1 90.6 10.2 9.3 4.6 90.9 94.5 93.7
EPEA 7.2 5.3 4.3 95.3 89.9 88.0 9.8 10.0 6.1 90.6 89.1 89.7
LEA 3.2 7.4 5.4 97.8 97.9 97.5 10.0 10.2 5.5 94.8 99.9 101.1
  -LEA 5.6 9.0 5.7 93.9 88.5 87.0 11.5 12.5 8.1 86.7 88.5 88.1
OEA 2.9 7.5 3.8 97.5 98.4 96.4 9.3 9.7 4.6 94.9 97.2 101.6
PEA 2.9 6.6 3.0 95.4 97.6 96.7 9.4 9.5 3.9 94.5 96.5 100.2
POEA 7.0 11.3 6.2 96.5 93.8 86.3 14.1 12.4 9.8 92.9 89.7 89.8
SEA 4.9 9.4 3.8 93.3 98.3 99.0 10.8 10.5 8.8 100.8 97.2 104
Data represent the mean values of QC sample replicates.






Time, 2 h at room 
temperature Time 0
Time, 2 h at room 
temperature Time 0
Time, 2 h at room 
temperature
EDTA   0.75 ± 0.21 8.51 ± 4.57 8.57 ± 2.23 102 ± 86.5 9.68 ± 2.28 115 ± 85.9
EDTA + 1.13 ± 1.03 11.8 ± 5.1 15.6 ± 2.30
Heparin   2.82 ± 0.67 30.6 ± 23.0 83.7 ± 12.8 876 ± 729 72.3 ± 0.93 619 ± 475
Heparin + 2.99 ± 0.05 65.3 ± 3.77 48.0 ± 1.20
Blood was collected in EDTA or heparin tubes. The separated plasma was analyzed immediately (time 0) or 
after incubation for 2 h at room temperature with or without addition of Orlistat to the plasma collection tube. 
Orlistat was added at 3.5   M to EDTA-plasma and at 15   M to heparin-plasma. Data are presented as mean ± SD of 
2/1-MG concentrations (ng/mL) of plasma from one volunteer in an experiment performed in duplicate.
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 The quantifi cation of ECs, as for all endogenous analytes, 
is challenging due to the absence of a blank matrix. Some 
authors have developed strategies of depletion of the analytes 
by processing the plasma using fi ve cycles of activated char-
coal ( 12 ). Other authors have used a surrogated analysis ap-
proach ( 18 ) or carried out quantifi cation by isotope dilution 
( 19, 20 ). It is to be noted that EC-depleted plasma still con-
tains MGs, probably due to its high concentrations ( 12 ). In 
this work, we have assessed the linearity, LOD, LLOQ, recov-
ery, matrix effect, and MG acyl migration stability of the 
method using deuterated analog forms as SAs and ISTDs. 
Our approach is valid because the original unaltered matrix 
can be used and, theoretically, the deuterated forms have the 
same properties as the authentic analytes. However, there are 
a limited number of deuterated analogs of ECs and ERCs, 
and in order to use this approach different deuterated ana-
log versions for each analyte are necessary. For this reason, in 
the analysis of samples of clinical studies (inhibition experi-
ments), and in determining the accuracy and imprecision of 
the method, quantifi cation was carried out with isotope dilu-
tion as described in the Materials and Methods. 
 Method validation 
 The method was linear for the ECs and ERCs whose 
quantifi cation was standardized. Results, which include the 
mathematically derived LODs and LLOQs, are shown in 
supplementary Table I. The experimentally verifi ed LLOQs 
of the method are the following: 0.02 ng/ml for AEA, DEA, 
DGLEA, EPEA,   -LEA, DHEA and POEA; 0.1 ng/ml for LEA; 
0.5 ng/ml for OEA and SEA; 0.75 ng/ml for 2-AG; 1 ng/ml 
for PEA; and 2.5 ng/ml for 2-OG and 2-LG. The LLOQs of 
PEA, OEA, and SEA were set at a higher concentration than 
their mathematical LLOQs due to small basal contaminant 
concentrations found in the solvents and glassware as re-
ported by other authors ( 12, 21 ). No signifi cant carry over was 
detected. No differences in the concentration values were 
found after reinjecting vials kept at 4°C for 24 h. Vials kept at 
  20°C were stable for all analytes except SEA. Recoveries 
were high (>80%) for all the analytes and matrix effect was 
substantial (40%) in some analytes such as 2-OG-d5. Minimal 
differences in the matrix effect of the six plasma sources were, 
however, observed due to being compensated by the use of 
deuterated analogs with similar ISTD structure ( Table 4 ). 
Within-run and between-run accuracy and imprecision values 
of NAEs and MGs are presented in  Table 5 and fi t current 
standard requirements for analytical method validation. With 
respect to the MGs, we found decreases in the concentration 
of the separate 2-MG isomers from day 2 of the validation pro-
tocol due to acyl migration during conservation of the plasma. 
This is explained in the section on stability of the isomeric ra-
tio of MGs. The method is deemed fi t for the determination 
of the EC and ERC profi le in human plasma samples. 
 Inhibition experiments of the ex vivo generation 
of MGs from plasma 
 Fanelli et al. ( 12 ) reported the generation of 2-AG in 
plasma in the absence of blood cells, with increases in 2/1-AG 
for plasma preserved for 4 h at 4°C or room temperature. In 
the course of our MG stability experiments, we observed 
to glycerol, is common to the fragmentation of MGs. The 
specifi c MRM transitions are listed in  Tables 1 and 2 . The 
method is selective and specifi c for each analyte with no 
cross contamination between MRM channels and, in most 
cases, a single chromatographic peak corresponding to 
the endogenous analyte was found throughout the acqui-
sition time. The variation in retention time of the individ-
ual analytes in a typical batch analysis was less than 0.5%. 
The retention time and product ion spectra of the endog-
enous analytes in the matrix matched the ones of the au-
thentic standards. 
 Fig.  4. Inhibition model of ex vivo production of 2-MG in plasma 
with Orlistat. Plasma from freshly extracted blood was spiked with 
a range of concentrations of Orlistat, incubated at room tempera-
ture for 2 h, and analyzed by LC/MS-MS to detect the levels of 
2-AG, 2-OG, and 2-LG. Values represent the normalized 2-MG lev-
els of three different volunteers analyzed in triplicate. 
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of DAGL. 2-OG and 2-LG originate from fat digestion in 
the intestinal lumen, where dietary triacylglycerol is hy-
drolyzed in the  sn -1 and  sn -3 position by pancreatic lipase 
through a series of directed stepwise reactions to diacylg-
lycerol (DAG) , 2-MG, fatty acids, and glycerol. 2-MGs 
are readily adsorbed and resynthesized to triacylglycer-
ols through the MG pathway ( 7, 25–27 ). Therefore, in 
terms of preventing 2-MG ex vivo formation, results ob-
tained from plasma samples spiked with Orlistat are in 
agreement with this inhibitory enzymatic activity. The bio-
synthetic origin of 2-AG, however, is presumably not related 
to fat digestion but to phospholipids. Arachidonate DAGs, 
the precursors of 2-AG, are originated by the hydrolysis of 
membrane phosphoinositides and they are converted to 
2-AG by the action of two  sn -1 selective DAGLs, DAGL  and 
DAGL  ( 16 ). Further, a direct dietary origin of 2-AG seems 
unlikely because arachidonic acid, an essential fatty acid 
and backbone of 2-AG structure, is present at low amounts 
in the diet, and is mainly obtained through metabolism of 
triacylglycerols that contain acyl-linoleoyl in their struc-
ture . The linoleic acid released is then elongated and un-
saturated to form arachidonic acid through the omega-6 
pathway. Additionally, we investigated the effect of the 
blood collection tube on MG generation. We found that 
MG concentrations were higher in heparin-plasma than in 
EDTA-plasma. The differences were maintained either for 
samples analyzed immediately or after incubation at room 
approximately 5-fold increases in 2/1-LG and 2/1-OG con-
centrations in plasma preserved for just 2 h at room tem-
perature compared with plasma preserved at 4°C. In regard 
to 2/1-AG, we observed differences in concentration when 
plasma was analyzed immediately after blood extraction ver-
sus some time afterwards (2 h), or after a freezing/thawing 
step even though cold chain (4°C) was maintained. We there-
fore investigated, in controlled experiments, several phos-
pholipase and lipase inhibitors for their capacity to inhibit 
ex vivo MG production in plasma. We found no inhibition 
activity for the phospholipase inhibitors D609, FIPI, and 
edelfosine (IC 50 >30   M, IC 50 >125 nM, and IC 50 >50   M, 
respectively). On the other hand, we observed inhibition of 
the ex vivo generation of 2-AG, 2-LG, and 2-OG in plasma 
spiked with Orlistat, a gastric and pancreatic lipase inhibitor 
( 22 ) and a potent nonspecifi c inhibitor of DAGL  and 
DAGL  ( 23 ). It is to be noted that the artifactual generation 
of MGs persisted even after immediate sample centrifugation 
that essentially eliminates all blood cells, which means that 
this MG buildup should be related to an enzymatic plasma 
activity. Because Orlistat is a general lipase inhibitor, we also 
tested the inhibition activity of RHC 80267, another non-
specifi c inhibitor of DAGL  ( 23 ), KT172, and KT109, potent 
selective DAGL  inhibitors ( 24 ). None of these com-
pounds showed inhibition activity (IC 50 >30   M, IC 50 >15   M, 
and IC 50 >15   M, respectively), which means that the ex vivo 
MG production in plasma is a mechanism independent 
 TABLE 7. Effect of Orlistat addition to plasma on EC measures 
EC/ERC n
Measured Concentration (ng/ml)
Change (%)  P Without Added Orlistat With Added Orlistat
2/1-AG 25 2.42 ± 1.10 0.89 ± 0.50   59.0 ± 23.9 <0.001
2/1-LG 25 15.2 ± 8.48 7.76 ± 3.54   47.2 ± 17.5 <0.001
2/1-OG 25 16.1 ± 10.4 8.93 ± 4.90   35.9 ± 25.0 <0.001
AEA 25 0.40 ± 0.19 0.39 ± 0.19   2.09 ± 9.58 0.225
DEA 25 0.12 ± 0.04 0.11 ± 0.04 0.45 ± 11.8 0.671
DGLEA 25 0.11 ± 0.03 0.12 ± 0.03   0.33 ± 12.3 0.324
DHEA 25 0.45 ± 0.19 0.44 ± 0.21   0.74 ± 10.9 0.801
EPEA 14 0.03 ± 0.01 0.03 ± 0.01   8.67 ± 9.02 0.104
LEA 25 1.30 ± 0.38 1.23 ± 0.38   4.05 ± 11.7 0.091
  -LEA 25 0.04 ± 0.01 0.04 ± 0.01   4.39 ± 13.4 0.142
OEA 25 3.16 ± 1.26 3.10 ± 1.22   1.72 ± 5.46 0.057
PEA 25 2.07 ± 0.67 2.06 ± 0.60 0.75 ± 9.20 0.774
POEA 25 0.18 ± 0.11 0.17 ± 0.10   2.90 ± 12.0 0.491
SEA 25 1.18 ± 0.33 1.15 ± 0.32   2.15 ± 8.81 0.214
Plasma of 25 female human volunteers was collected with or without addition of Orlistat (3.4   M) and stored 
at   80°C until EC analysis. Data are presented as mean ± SD. EPEA concentration was below the LLOQs for some 
of the samples. The effect of Orlistat addition to plasma on EC measures was assessed by a paired-samples  t -test.
 TABLE 8. Stability of the isomerization of spiked 2/1-AG-d5 and 2/1-OG-d5 in stored plasma 
Ratio
Spiked analyte Time 0
Time, 30 min at 
room temperature Time, 20 days at   20°C Time, 20 days at   80°C
2-AG-d5 ISO1/ISO2 0.08 ± 0.001 0.46 ± 0.06 0.84 ± 0.05 0.41 ± 0.01
1-AG-d5 ISO2/ISO1 0.01 ± 0.01 0.04 ± 0.005 0.07 ± 0.003 0.03 ± 0.002
2-OG-d5 ISO1/ISO2 0.08 ± 0.01 0.36 ± 0.06 0.58 ± 0.03 0.36 ± 0.06
1-OG-d5 ISO2/ISO1 0.13 ± 0.03 0.13 ± 0.03 0.12 ± 0.04 0.13 ± 0.03
A pool of plasma was spiked separately with the deuterated analogs of the isomer 1 (ISO1) and isomer 2 
(ISO2) of AG and OG. Aliquots were distributed in cryotubes and chemical stability of the isomer ratio (ISO1/ISO2 
and ISO2/ISO1) was assessed upon conservation at time 0, 30 min at room temperature, 20 days at   20°C, or 20 
days at   80°C. Data are presented as mean ± SD of replicate analysis.
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the 25 human female samples ( Table 7 ), with the excep-
tion of EPEA that, due to its low levels, could only be quan-
tifi ed in 14 samples. In summary, data show that Orlistat 
addition as part of the sample collection protocol can be a 
tool to stabilize MG concentrations in plasma, and this can 
aid in the harmonization of EC and ERC measurements in 
clinical samples. 
 Stability of the isomeric ratio of MGs 
 The results of the stability experiment of MGs in plasma 
show that the chemical isomerization of isomer 2 to isomer 
1 decreases with decreases in the preservation temperature 
of the plasma before analysis. However, isomerization is still 
observed, even if samples are stored at   80°C ( Table 8 ). 
Furthermore, it has been reported that isomerization is also 
dependent on the amount of serum albumin present in the 
sample ( 17 ). It is, therefore, possible that even when sam-
ples are subjected to the same storage conditions, they 
could still have different chemical isomerization rates. Ad-
ditionally, chemical isomerization takes place in plasma 
preserved for a very short time at room temperature. 
 We also investigated the endogenous origin of MG iso-
mers in fresh plasma samples ( Table 9 ). As has been previ-
ously suggested ( 14 ), our data support the hypothesis that 
1-AG does not have an endogenous origin and is the result 
of chemical isomerization during sample storage and pro-
cessing, because in fresh plasma samples we found that 
1-AG was present at the same isomeric ratio as the pure 
standard mixture. On the other hand, we observed that 
1-LG and 1-OG were present at substantial concentrations. 
1-MG originates from the in vivo isomerization of 2-MG 
during digestion and absorption. It has been estimated 
that approximately 25% of 2-MG is isomerized to the 1-MG 
form. However, 2-MG is the predominant form in which 
MGs are absorbed and resynthesized to triacylglycerols, 
while 1-MGs are eventually hydrolyzed by pancreatic lipase 
to free fatty acids and glycerol ( 25–27, 30 ). 
 In summary, only EC analysis performed with fresh sam-
ples is able to quantify the original isomeric ratio of the 
sample. Studies that report MG concentrations should spec-
ify whether the concentration data are from the separate or 
combined 1 and 2 isomers. Due to the instability of isomer-
ization during conservation, and the fact that the 1-MG iso-
mer originates either in vivo or ex vivo from the 2-MG 
isomer, studies that report the concentration of the two iso-
mers together may still provide meaningful data for the in-
terpretation of its biological signifi cance in a fi t-for-purpose 
approach. Alternatively, clinical samples may be spiked with 
deuterated analogs of known isomer ratios before conserva-
tion in order to correct the concentration data. 
 CONCLUSIONS 
 MG analysis is a challenging issue; to our knowledge, this 
is the fi rst time that an enzymatic activity inhibited by the 
lipase inhibitor Orlistat and able to generate MGs in plasma 
in the absence of cells has been reported. Our fi ndings sug-
gest that, as happens with EC brain concentrations ( 31 ), 
temperature. Orlistat was able to inhibit MG production in 
plasma originated from both kind of tubes, but due to the 
higher MG buildup in heparin-plasma, a higher concen-
tration of Orlistat was needed to achieve full inhibition 
( Table 6 ). Further, because heparin-plasma is commonly 
used for the assay of lipoprotein lipase due to its affi nity for 
heparin ( 28 ), we also tested the inhibition activity of GSK 
264220A, an endothelial lipase and a lipoprotein lipase in-
hibitor ( 29 ), but we found no inhibition (IC 50 >15   M) on 
EDTA-plasma or heparin-plasma. The reason for the lower 
MG concentrations on EDTA-plasma is probably due to the 
chelate effect of EDTA on the cofactors needed for MG 
biosynthesis. We recommend, therefore, the use of EDTA 
blood tubes for collection in addition to Orlistat. In a sec-
ond set of experiments, EDTA-plasma of three human vol-
unteers was used for the calculation of the IC 50 of Orlistat 
for the ex vivo generation of 2-AG, 2-LG, and 2-OG. An in-
hibition model was obtained and the data is graphically pre-
sented in  Fig. 4 . The IC 50 of Orlistat with the mean, its 95% 
confi dence interval, and the coeffi cient of determination 
(R 2 ) of the inhibition model are as follows: 285.6 nM [212.4, 
384.0] for 2-AG (R 2 = 0.8809), 146.1 nM [104.9, 203.4] for 
2-LG (R 2 = 0.9087), and 148.7 nM [110.6, 200.0] for 2-OG 
(R 2 = 0.9254). 
 Stabilization of MG measures in plasma spiked 
with Orlistat 
 The ex vivo generation of MG in plasma can be prevented 
by Orlistat. Because our MG assay was done at room tem-
perature, we tested, in controlled conditions, whether Or-
listat addition to the plasma storage tube had any effect on 
MG measures when a typical clinical sample collection pro-
tocol was followed. For that, 25 female blood samples were 
collected and processed in a matter of weeks, maintaining 
the cold chain until they were fi nally stored at   80°C. EC 
analysis took place several weeks after all samples had been 
collected and was done with our standard sample prepara-
tion procedure. The results are presented in  Table 7 and 
they show that Orlistat addition during the sample collec-
tion protocol leads to a signifi cant reduction of all MG 
measures (36–59%,  P < 0.001). The NAEs, which are the 
other measures of our EC and ERC analysis, were not af-
fected by the addition of Orlistat. We think that differences 
may have arisen due to the enzymatic activity that took in 
the freezing/thawing and processing steps. All the NAEs 
and MGs described in the method could be quantifi ed in 
 TABLE 9. Stability of the isomerization of endogenous 2/1-AG, 
2/1-LG, and 2/1-OG in stored plasma 
Ratio ISO1 / ISO2
Endogenous analyte Time 2 h at 4°C Time 2 h at room temperature
2/1-AG 0.09 ± 0.10 0.32 ± 0.24
2/1-LG 0.43 ± 0.13 0.76 ± 0.10
2/1-OG 0.28 ± 0.08 0.57 ± 0.06
The stability of the isomer 1/isomer 2 (ISO1/ISO2) ratio of 
endogenous 2/1-AG, 2/1-LG, and 2/1-OG was assessed in plasma of 
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peripheral EC concentrations from clinical studies or ani-
mal models greatly depend on sample collection and sam-
ple time processing conditions that take place in the clinical 
and laboratory settings due to the natural presence of enzy-
matic activity in plasma. Because of the instability of EC 
concentrations in blood, EC studies need to follow strict 
harmonized sample collection and processing protocols in 
order to avoid artifi cial differences between samples. Fi-
nally, the collection of plasma samples with Orlistat may be 
a useful tool in the determination of real endogenous 2-MG 
concentrations. In addition to immediate centrifugation in 
refrigerated conditions and separation of plasma from 
blood to avoid the release of NAE from blood cells, we also 
recommend the addition of Orlistat to plasma collecting 
tubes and maintaining the cold chain until storage and pro-
cessing. Orlistat is inexpensive, and thus may be a cost effec-
tive measure to aid in the harmonization of EC and ERC 
measurements in clinical research. Data suggest that the ex 
vivo generation of MG in plasma is a mechanism indepen-
dent of DAGL, because besides the general lipase inhibitor 
Orlistat, other specifi c or unspecifi c DAGL inhibitors do 
not inhibit MG generation, and neither is the result of en-
dothelial lipase or lipoprotein lipase activity. The full char-
acterization of this enzymatic activity goes beyond the scope 
of this work, but due to the importance of the EC 2-AG as a 
biomarker, the understanding of this apparent alternative 
biosynthetic pathway of 2-AG, probably linked to lipid me-
tabolism, would contribute to a better comprehension of 
the signifi cance of its blood concentrations . 
 We have validated a method for the determination of a 
range of MGs and NAEs in plasma. The developed method 
is able to preserve the original isomeric ratio of MGs. We 
have found that the chemical isomerization of MGs can 
only be avoided by immediate processing (at cold tempera-
ture and acid pH) and analysis of samples. The report of 
MGs as the sum of both isomers may be considered. Alter-
natively, appropriate isomerization controls can be used 
during sample collection and conservation in order to cor-
rect concentrations. Data suggest that isomer 1 of AG is not 
an endogenous compound, and most probably is the result 
of chemical isomerization during storage and sample pro-
cessing. On the other hand, isomer 1 of OG and isomer 1 of 
LG are likely to be endogenous compounds that result from 
in vivo isomerization that takes places during digestion, and 
their concentrations can be detected in plasma.  
 REFERENCES 
  1 .  Montecucco ,  F. , and  V.  Di Marzo .  2012 .  At the heart of the matter: 
the endocannabinoid system in cardiovascular function and dys-
function.  Trends Pharmacol. Sci.  33 :  331 – 340 . 
  2 .  Bilkei-Gorzo ,  A.  2012 .  The endocannabinoid system in normal and 
pathological brain ageing.  Philos. Trans. R. Soc. Lond. B Biol. Sci. 
 367 :  3326 – 3341 . 
  3 .  Giuffrida ,  A. , and  A.  Seillier .  2012 .  New insights on endocannabinoid 
transmission in psychomotor disorders.  Prog. Neuropsychopharmacol. 
Biol. Psychiatry .  38 :  51 – 58 . 
  4 .  Ashton ,  C. H. , and  P. B.  Moore .  2011 .  Endocannabinoid system 
dysfunction in mood and related disorders.  Acta Psychiatr. Scand. 
 124 :  250 – 261 . 
  5 .  Monteleone ,  P.  2011 .  New frontiers in endocrinology of eating dis-
orders.  Curr. Top. Behav. Neurosci.  6 :  189 – 208 . 
2-Monoacylglycerols: ex vivo generation and isomerization 977
involved in macrophage infl ammatory responses.  Nat. Chem. Biol. 
 8 :  999 – 1007 . 
 25 .  Mattson ,  F. H. , and R. A. Volpenhein.  1964 .  The digestion and ab-
sorption of triglycerides.  J. Biol. Chem.  239 :  2772 – 2777 . 
 26 .  Mu ,  H. , and  C. E.  Høy .  2004 .  The digestion of dietary triacylglycer-
ols.  Prog. Lipid Res.  43 :  105 – 133 . 
 27 .  Kindel ,  T. ,  D. M.  Lee , and  P.  Tso .  2010 .  The mechanism of the forma-
tion and secretion of chylomicrons.  Atheroscler. Suppl.  11 :  11 – 16 . 
 28 .  Karpe ,  F. ,  T.  Olivecrona ,  G.  Walldius , and  A.  Hamsten .  1992 . 
 Lipoprotein lipase in plasma after an oral fat load: relation to free 
fatty acids.  J. Lipid Res.  33 :  975 – 984 . 
 29 .  Goodman ,  K. B. ,  M. J.  Bury ,  M.  Cheung ,  M. A.  Cichy-Knight ,  S. 
E.  Dowdell ,  A. K.  Dunn ,  D.  Lee ,  J. A.  Lieby ,  M. L.  Moore ,  D. A. 
 Scherzer ,  et al .  2009 .  Discovery of potent, selective sulfonylfuran 
urea endothelial lipase inhibitors.  Bioorg. Med. Chem. Lett.  19 : 
 27 – 30 . 
 30 .  Hofmann ,  A. F. , and  B.  Borgstrom .  1963 .  Hydrolysis of long-chain 
monoglycerides in micellar solution by pancreatic lipase.  Biochim. 
Biophys. Acta .  70 :  317 – 331 . 
 31 .  Buczynski ,  M. W. , and  L. H.  Parsons .  2010 .  Quantifi cation of brain 
endocannabinoid levels: methods, interpretations and pitfalls.  Br. 
J. Pharmacol.  160 :  423 – 442 . 
